DC-CIK细胞免疫治疗联合化疗对复发性卵巢癌患者免疫功能、凝血功能及肿瘤干细胞标志物的影响  

Effects of DC-CIK cell immunotherapy combined with chemotherapy on immune function,coagulation function and tumor stem cell markers in patients with recurrent ovarian cancer

作　　者：武加利[1] 方延宁[1] 李红[2] 

机构地区：[1]济宁市第一人民医院妇产科,山东济宁272002 [2]济宁市第一人民医院超声科,山东济宁272002

出　　处：《海南医学院学报》2017年第23期3282-3285,3289,共5页Journal of Hainan Medical University

基　　金：济宁市科技发展计划项目(No.2013jnwk56)~~

摘　　要：目的:探讨树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)免疫治疗联合化疗对复发性卵巢癌患者免疫功能、凝血功能及肿瘤干细胞标志物的影响。方法:选取80例于我院接受治疗的复发性卵巢癌患者作为研究对象,根据是否接受细胞免疫治疗分为单纯化疗组(n=35)及联合治疗组(n=45),单纯化疗组给予常规TC方案化疗,联合治疗组给予DC-CIK细胞免疫治疗联合TC方案化疗,两组均以21d为一个周期,共治疗3个周期;比较治疗前及治疗结束7d后患者免疫功能、凝血功能及肿瘤干细胞标志物水平变化。结果:治疗结束7d后,联合治疗组CD3^+、CD3^+CD4^+、CD4^+/CD8^+、NK细胞数目均显著高于治疗前,CD4^+CD25^+数目显著低于治疗前,且联合治疗组治疗后外周血T细胞亚群各细胞改善情况均优于单纯化疗组,差异均具有统计学意义(P<0.05);治疗结束7d后,两组FIB水平均较治疗前显著降低,差异均具有统计学意义(P<0.05);治疗结束7d后,两组CD133、DDX4水平均显著低于治疗前,且联合治疗组显著低于单纯化疗组,差异均具有统计学意义(P<0.05)。结论:应用DCCIK细胞免疫联合化疗治疗复发性卵巢癌可明显增强患者免疫力,改善FIB水平,调节患者血清肿瘤干细胞标志物水平,对改善患者预后具有积极意义,值得在临床上推广应用。Objective:To investigate the effects of immunotherapy with dendritic cells(DC)-cytokine induced killer cells(CIK)combined with chemotherapy on immune function,coagulation function and tumor stem cell markers in patients with recurrent ovarian cancer.Methods:80 cases in our hospital for treatment of recurrent ovarian cancer patients were selected as the research object,they were divided into chemotherapy group(n=35)and combined treatment group(n=45)according to whether or not to receive cellular immunotherapy,chemotherapy group received TC chemotherapy,combined therapy group were given DC-CIK cell immunotherapy combined with TC chemotherapy group,the two groups were treated with 21 dfor a cycle,3 cycles were treated;The changes of immune function,coagulation function and tumor stem cell markers were compared between the day of blood collection and the end of treatment for 7 d.Results:After the end of treatment for 7 d,the CD3^+,CD3^+CD4^+,CD4^+/CD8^+,NK cell number of combined treatment group were significantly higher than that of blood collection day,the number of CD4^+CD25^+was significantly lower than that of blood collection day,The improvement of peripheral blood T lymphocyte subsets in the combined treatment group was better than that in the chemotherapy group(P<0.05);After the end of treatment for 7 d,the FIB levels of two groups were significantly decreased than those of the blood collection day,the difference was statistically significant(P<0.05);After the end of treatment for 7 d,the CD133 and DDX4 levels of two groups were significantly lower than that of the blood collection day,and the combined treatment group was significantly lower than the chemotherapy group,the difference were statistically significant(P<0.05).Conclusions:DC-CIK cell immunotherapy combined with chemotherapy can significantly improve the immunity and the level of FIB of patients with recurrent ovarian cancer,and regulating the level of serum tumor stem cell markers in patients,it has positive significance to improve the prognosis o

关 键 词：复发性卵巢癌 DC-CIK T细胞亚群 凝血功能 肿瘤干细胞标志物 

分 类 号：R737.37[医药卫生—肿瘤]